Biobanks are structured depositories where biological specimens in the form of tissues, blood, DNA, cells, and other biological and related health and demographic information are collected, processed, stored, and handled. These samples are maintained with standardized conditions to maintain quality and usability over time, to be used in research and clinical purposes. Also, biobanks are important in enhancing biomedical research, drug development, clinical diagnostics, and personalized medicine by providing access to high-quality, well-annotated biological specimens to the researcher. They enhance research in genomics, disease mechanisms, biomarker discovery, and therapy development, leading to significant improvements in healthcare outcomes and scientific innovation.

The Biobanks Market is set to show a growth rate of about 8.8% during the forecast period (2025-2033F). The global biobanks market is accelerating due to the growing demand for personalized medicine, improved diagnostic accuracy, and the development of therapeutic methods that require high-quality biological samples. Advances in sectors such as genomics, proteomics, and biotechnology have increased the need for proper organization and long-term storage of samples. Additionally, further increases in clinical research, drug discovery, and regenerative medicine investments contribute to the market growth. Moreover, the provision of government funding, favorable regulatory environments, and increased partnerships between academic institutions, pharmaceutical firms, and research organizations are enhancing biobanking infrastructures.

List of Top Companies Operating in Biobanks Worldwide:

The global biobanks market has several major players, including Thermo Fisher Scientific Inc., Merck KGaA, Lonza, Charles River Laboratories, and Qiagen. More information about these companies has been provided below:

1. Thermo Fisher Scientific Inc.

Thermo Fisher Scientific Inc. provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in North America, Europe, Asia-Pacific, and internationally. The company’s Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bioproduction to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.

Access sample report (including graphs, charts, and figures): https://univdatos.com/reports/biobanks-market?popup=report-enquiry

2. Merck KGaA

Merck KGaA operates as a science and technology company in Germany. It operates through Life Science, Healthcare, and Electronics segments. The company’s Life Science segment offers tools, chemicals, and equipment for academic labs, biotech, and pharmaceutical manufacturers, as well as the industrial sector. This segment provides drug manufacturers with process development expertise and technologies, such as continuous bioprocessing; testing kits and services; reagents and services; testing solutions that analyze air, water, and soil; and testing and tools, as well as products that help test nutritional value and identify quality inconsistencies. Its Healthcare segment discovers, develops, manufactures, and markets prescription drugs and biopharmaceuticals for the treatment of oncology, neurology, and immunology, fertility, endocrinology, as well as cardiovascular, diabetes, thyroid disorders, and multiple sclerosis; general medicines; and injection device and disease monitoring software.

3. Lonza

Lonza Group AG, together with its subsidiaries, supplies various products and services for pharmaceutical, biotech, and nutrition markets in Europe, North and Central America, Latin America, Asia, Australia, New Zealand, and internationally. It operates through Biologics, Small Molecules, Cell & Gene, and Capsules & Health Ingredients segments. The Biologics segment engages in the contract development and manufacturing of biopharmaceuticals for clinical and commercial manufacturing needs throughout the product lifecycle, including drug substance and drug product manufacturing. The Small Molecules segment operates as an integrated development and manufacturing service provider for small molecule drug substances and their intermediates. This segment also supports customers across various aspects of design, development, and manufacturing, including partic le engineering and drug product packaging. The Cell & Gene segment develops technologies and platforms that industrialize the manufacturing processes and production of cell and gene therapies; offers contract development and manufacturing services, and regulatory support for a range of allogeneic and autologous cell therapies, and exosome-based therapies, as well as viral vector gene therapies.

4. Charles River Laboratories

Charles River Laboratories International, Inc. provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing). The DSA segment offers early and in vivo discovery services for the identification and validation of novel targets, chemical compounds, and antibodies through the delivery of preclinical drug and therapeutic candidates ready for safety assessment; and safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism, and pharmacokinetics services. This segment also offers specialized testing of biologics for pharmaceutical and biotechnology companies.

5. Qiagen

QIAGEN is a leading global provider of “Sample to Insight” solutions that enable customers to extract, process, and analyze DNA, RNA, and proteins from biological samples to generate meaningful molecular insights for research and clinical decision-making. Its comprehensive portfolio includes kits, instruments, automation, and bioinformatics tools that support molecular diagnostics, life sciences research, and applied testing across healthcare, pharmaceutical, and academic sectors. Over 500,000 customers worldwide rely on QIAGEN’s technologies to accelerate discovery, improve diagnostics, and guide treatment strategies, making it a key partner in advancing science and improving global health outcomes. 

Related Reports:-

Biotechnology Market: Current Analysis and Forecast (2021-2027)

Digital Pathology Market: Current Analysis and Forecast (2021-2027)

Blood Clot Retrieval Devices Market: Current Analysis and Forecast (2025-2033)

Southeast Asia Pacemakers Market: Current Analysis and Forecast (2025-2033)

Premenstrual Syndrome Treatment Market: Current Analysis and Forecast (2025-2033)

Contact Us:

UnivDatos

Contact Number - +1 978 733 0253

Email - contact@univdatos.com 

Website - www.univdatos.com

Linkedin- https://www.linkedin.com/company/univ-datos-market-insight/mycompany/